
The Culprit Impeding Drug Competition Is Not Who The Feds Expected
The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry.
The title of the first session—"Anticompetitive Conduct by Pharmaceutical Companies"—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists had refocused the spotlight onto pharmacy benefit managers—and provided striking evidence that PBMs, not biotech companies, deserve most of the blame for the anticompetitive practices that lead to high drug prices.
If the FTC and DOJ heed the panelists' warnings and crack down on this misbehavior, it could tangibly reduce drug costs for patients.
PBMs decide which medicines are included on insurers' formularies, or lists of covered drugs. That gatekeeping authority gives PBMs the power to negotiate prices with manufacturers and secure rebates.
PBMs claim to use those rebates to reduce costs for patients. But the rebate structure actually gives them a strong incentive to prefer higher-priced drugs—even when cheaper and equally effective alternatives are available. That's because their earnings are generally determined as a percentage of a drug's list price.
A 2024 House Oversight Committee report identified more than 1,000 instances in which PBMs favored higher-cost medicines over less expensive equivalents. In 300 of those examples, PBMs' preferred medicines cost patients at least $500 more than an alternative they excluded from their formularies.
Formulary decisions like these lead to larger rebates and fees for PBMs—while the costs pile up for patients. According to a 2023 analysis, PBMs collect more than 40 cents of every dollar spent on brand-name medicines by commercial health plans.
PBMs' perverse incentives go beyond the financial. As the FTC's and DOJ's panelists explained, PBMs' behavior stifles competition and innovation in the drug industry by crushing the development of generic and biosimilar drugs.
Biosimilars, which are clinically similar versions of existing "biologic" drugs grown from living cell cultures, typically debut at prices that are more than 40% lower than the brand-name version's launch price. In some cases, biosimilars launch at prices that are 81% lower.
But even after a year on the market, the average biosimilar commands just under 20% market share for its therapeutic line. PBMs frequently exclude these lower-cost—and thus lower-rebate—biosimilars from formularies or lock them behind prior authorization and "fail-first" requirements.
In cases when PBMs do include biosimilars in their formularies, they're often artificially pricey "private-label" drugs affiliated with the PBMs themselves.
Juliana Reed, the executive director of the nonprofit Biosimilars Forum, highlighted a particularly egregious example involving the blockbuster autoimmune drug Humira, which has 10 biosimilar competitors—that collectively account for less than 10% of U.S. market share.
As James Gelfand—president and CEO of the ERISA Industry Committee, an organization representing large employer health plans—stated, "[t]his manipulation undercuts biosimilar sustainability." It dramatically limits biosimilar manufacturers' ability to establish themselves in the market and earn a return on their products.
In fact, it's creating what the FTC and DOJ panelists termed a "biosimilar void"—a dramatic collapse in new biosimilar development.
According to a recent IQVIA study, 118 biologic drugs will lose patent protection in the next decade. But biotech companies are currently developing biosimilar competitors for just 12 of them. There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.
Manufacturers of traditional chemically synthesized generic drugs face many of the same hurdles. The House Oversight Committee report found that "[n]ew generic drugs are experiencing historically slow adoption by patients directly resulting from PBM coverage decisions."
The FTC and DOJ may not have recognized just how severely PBMs have undermined competition across the drug market. But it's not too late to solve the problem.
The three largest PBMs—Caremark, Express Scripts, and OptumRx—are each integrated with a major pharmacy and together control nearly 80% of U.S. prescriptions. The nation's six largest PBMs account for almost 95% of all prescriptions dispensed.
If any industry deserves to face antitrust scrutiny, it's this one. Putting a stop to PBMs' anticompetitive practices would be far more fruitful than imposing new price controls or other regulations on manufacturers. Policymakers should also consider requiring PBMs to pass negotiated rebates directly to patients, so beneficiaries see real savings at the pharmacy counter.
The recent listening session has given our leaders an actionable path to reform of the market for prescription drugs. Fix PBMs, and concerns about drug prices will resolve themselves.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
How The J. M. Smucker Company (SJM) Fits into the Food Dividend Stock Portfolio
The J. M. Smucker Company (NYSE:SJM) is included among the 10 Best Food Stocks with Dividends. A wholesaler distributing peanut butter, fruit spreads and specialty spreads to a retailer. The J. M. Smucker Company (NYSE:SJM) is recognized as a strong value in the food sector, with several successful brands under its belt. Notable performers include pet food lines like Meow Mix and Milk-Bone, as well as the well-liked Uncrustables sandwich products. The company paid a premium when it acquired Hostess Brands in November 2023. To refocus its efforts, the company recently sold off some brands from its Sweet Baked Snack segment, including Voortman, to concentrate more on the Hostess portfolio. Although the transition has been challenging, The J. M. Smucker Company (NYSE:SJM) appears to be moving in the right direction. It anticipates full-year fiscal 2026 sales to grow by 2% to 4%, despite the effects of divesting certain Sweet Baked Snack value brands. The company is also expected to deliver strong earnings and free cash flow. In fiscal Q4 2025, The J. M. Smucker Company (NYSE:SJM) reported operating cash flow of $393.9 million, and its free cash flow was $298.9 million. During the quarter, the company returned $114.5 million to shareholders through dividends, reinforcing its commitment to investor return. This cash position enables the company to consistently raise its dividends. The J. M. Smucker Company (NYSE:SJM) declared a 1.9% hike in its quarterly dividend on July 16. This marked the company's 24th consecutive year of dividend growth, which makes it one of the best food stocks with dividends. The company now offers a quarterly dividend of $1.10 per share and has a dividend yield of 4.04%, as of July 27. While we acknowledge the potential of SJM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None.
Yahoo
24 minutes ago
- Yahoo
Why Flowers Foods (FLO) is a Top Food Stock for Dividend Investors
Flowers Foods, Inc. (NYSE:FLO) is included among the 10 Best Food Stocks with Dividends. A female baker in a spotless kitchen carefully decorating a cake. Flowers Foods, Inc. (NYSE:FLO) is an American company that manufactures a range of bakery products for both retail and foodservice markets nationwide. Its offerings include items like fresh bread, buns, rolls, snack cakes, and tortillas. The company supplies these products to grocery stores, convenience outlets, and restaurants. Among its most recognized brands are Nature's Own, Whitewheat, Cobblestone Bread, Wonder, Dave's Killer Bread, Canyon Bakehouse, Mrs. Freshley's, and Tastykake. Flowers Foods, Inc. (NYSE:FLO) has a strong cash position. In the most recent quarter, the company generated $135.6 million in operating cash flow, which grew by $30.5 million. The company also remained committed to its shareholder obligation, returning $52.3 million through dividends during the quarter, up $1.2 million from the previous quarter. Flowers Foods, Inc. (NYSE:FLO) currently offers a quarterly dividend of $0.2475 per share, having raised it by 3.1% in May. This was the company's 23rd consecutive year of dividend growth, which makes it one of the best food stocks with dividends. In addition, it has paid regular dividends to shareholders for 91 quarters in a row. The stock has a dividend yield of 6.09%, as of July 27. While we acknowledge the potential of FLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None.
Yahoo
24 minutes ago
- Yahoo
Vice President JD Vance is on the road again to sell the Republicans' big new tax law
COLUMBUS, Ohio (AP) — Vice President JD Vance is hitting his home state on Monday to continue promoting the GOP's sweeping tax-and-border bill. He will be in Canton, Ohio, to talk about the bill's 'benefits for hardworking American families and businesses,' according to his office. Aides offered little detail in advance about the visit, but NBC News reported that his remarks will take place at a steel plant in Canton, located about 60 miles south of Cleveland. The visit marks Vance's second trip this month to sell the package, filled with a hodgepodge of conservative priorities that Republicans have dubbed the 'One Big, Beautiful Bill' as the vice president becomes its chief promoter on the road. In West Pittston, Pennsylvania, Vance told attendees at an industrial machine shop that they should be able to keep more of their pay in their pockets, highlighting the law's new tax deductions on overtime. Vance also discussed a new children's savings program called Trump Accounts and how the new law promotes energy extraction, while decrying Democrats for opposing the bill that keeps the current tax rates, which would have otherwise expired later this year. The legislation cleared the GOP-controlled Congress by the narrowest of margins, with Vance breaking a tie vote in the Senate for the package that also sets aside hundreds of billions of dollars for Trump's immigration agenda while slashing Medicaid and food stamps. The vice president is also stepping up his public relations blitz on the bill as the White House tries to deflect attention away from the growing controversy over Jeffrey Epstein. The disgraced financier killed himself, authorities say, in a New York jail cell in 2019 as he awaited trial on sex trafficking charges. Trump and his top allies stoked conspiracy theories about Epstein's death before Trump returned to the White House and are now reckoning with the consequences of a Justice Department announcement earlier this month that Epstein did indeed die by suicide and that no further documents about the case would be released. Questions about the case continued to dog Trump in Scotland, where he on Sunday announced a framework trade deal with the European Union. Asked about the timing of the trade announcement and the Epstein case and whether it was correlated, Trump responded: 'You got to be kidding with that." 'No, had nothing to do with it,' Trump told the reporter. 'Only you would think that." The White House sees the new law as a clear political boon, sending Vance to promote it in swing congressional districts that will determine whether Republicans retain their House majority next year. The northeastern Pennsylvania stop is in the district represented by Republican Rep. Rob Bresnahan, a first-term lawmaker who knocked off a six-time Democratic incumbent last fall. On Monday, Vance will be in the district of Democratic Rep. Emilia Sykes, who is a top target for the National Republican Congressional Committee this cycle. Polls before the bill's passage showed that it largely remained unpopular, although the public approves of some individual provisions such as increasing the child tax credit and allowing workers to deduct more of their tips on taxes.